Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review

被引：0
|
作者：
Zeeshanuddin Ahmad
Amar Jain
Nikhil Mehta
Elroy Saldanha
Dhruv Patel
Sanjay M. Desai
机构：
[1] Sri Aurobindo Medical College and Post Graduate Institute,Department of Surgical Oncology
来源：
Indian Journal of Gynecologic Oncology | 2019年 / 17卷
关键词：
Epithelial ovarian cancer (EOC); Primary cytoreductive surgery (PCS); Interval debulking surgery (IDS); Neoadjuvant chemotherapy (NACT);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Should neoadjuvant chemotherapy be preferred to an alternative treatment for advanced ovarian cancer: Comparison of neoadjuvant chemotherapy followed by interval debulking surgery and primary debulking surgery in patients with advanced ovarian cancer
    Liu, J.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 176 - 176
  • [32] Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Propensity-matched Analysis
    Siesto, Gabriele
    Cavina, Raffaele
    Romano, Fabrizio
    Vitobello, Domenico
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (03): : 280 - 285
  • [33] The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery
    Bizzarri, Nicolo
    Marchetti, Claudia
    Conte, Carmine
    Loverro, Matteo
    Giudice, Maria Teresa
    Quagliozzi, Lorena
    Distefano, Mariagrazia
    Chiantera, Vito
    Scambia, Giovanni
    Fagotti, Anna
    GYNECOLOGIC ONCOLOGY, 2022, 165 (03) : 453 - 458
  • [34] MINIMALLY INVASIVE VERSUS OPEN INTERVAL DEBULKING SURGERY AFTER NEOADJUVANT CHEMOTHERAPY FOR OVARIAN CANCER
    Margul, D.
    Seagle, B. L.
    Yang, J.
    Ann, P.
    Alexander, A.
    Kocherginsky, M.
    Shahabi, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 760 - 760
  • [35] Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
    Trope, Claes G.
    Elstrand, Mari B.
    Sandstad, Berit
    Davidson, Ben
    Oksefjell, Halldis
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (14) : 2146 - 2154
  • [36] Toxicity and survival associated with IV/IP chemotherapy following neoadjuvant chemotherapy and interval debulking surgery for epithelial ovarian, fallopian tube, and primary peritoneal cancer
    Rios-Doria, E.
    Pezzillo, M.
    Ulm, M. A.
    Tillmanns, T.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 127 - 128
  • [37] A comparison of postoperative morbidity in open versus robotic-assisted interval debulking surgery for epithelial ovarian cancer patients following neoadjuvant chemotherapy
    Zhang, Y.
    Staley, A.
    Tucker, K.
    Paraghamian, S. E.
    Wang, M.
    Clark, L. H.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 138 - 138
  • [38] Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery
    Pepin, Kristen
    Bregar, Amy
    Davis, Michelle
    Melamed, Alexander
    Hinchcliff, Emily
    Gockley, Allison
    Horowitz, Neil
    del Carmen, Marcela G.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (03) : 612 - 616
  • [39] Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery
    Pepin, K. J.
    Davis, M. R.
    Bregar, A. J.
    Melamed, A.
    Hinchcliff, E. M.
    Gockley, A. A.
    del Carmen, M. G.
    Horowitz, N. S.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 140 - 140
  • [40] Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma
    Seward, Shelly M.
    Winer, Ira
    CANCER AND METASTASIS REVIEWS, 2015, 34 (01) : 5 - 10
12345